Related Experiment Videos
Effect of acute and chronic misonidazole administration on peripheral-nerve electrophysiology in mice
Abstract:
I.p. administration at several dose levels over periods of up to 12 weeks, or continuous i.v. infusion of high doses of misonidazole (MISO) for 15 h, produced no significant change in peripheral nerve conduction velocity (NCV) and did not prevent the normal increase in NCV as the animals matured from 12 to 24 weeks of age. Peripheral NCV (sural nerve) was reduced in both MISO-treated and control mice with hind-limb tumour implants, presumably owing to physical pressure due to tumour growth. In addition, neither the medial nerves nor the tibial nerve in the normal limbs of the tumour-implanted, drug-treated animals showed any change. Consequently our earlier and present studies do not confirm the recent reports of changes in NCV following either acute or chronic MISO administration to mice.
Insights
Misonidazole (MISO) administration did not affect nerve conduction velocity in mice. Tumor growth, not MISO, caused reduced nerve function in affected limbs, contradicting previous reports.
Area of Science:
- Neuroscience
- Pharmacology
- Oncology
Background:
- Misonidazole (MISO) is a hypoxic cell radiosensitizer used in cancer therapy.
- Previous studies suggested MISO may cause peripheral neuropathy, indicated by changes in nerve conduction velocity (NCV).
Purpose of the Study:
- To investigate the effects of acute and chronic Misonidazole (MISO) administration on peripheral nerve conduction velocity (NCV) in mice.
- To determine if MISO affects normal NCV maturation or NCV in tumor-bearing animals.
Main Methods:
- Mice received intraperitoneal injections or continuous intravenous infusions of MISO at various doses and durations.
- NCV was measured in peripheral nerves (sural, medial, tibial) over time.
- Tumor-bearing mice were included to assess MISO's effect in the presence of tumor-induced compression.
Main Results:
- Neither acute nor chronic MISO administration significantly altered NCV in healthy mice.
- MISO did not impede the normal age-related increase in NCV.
- Reduced NCV in tumor-bearing mice was attributed to physical pressure from tumor growth, affecting both MISO-treated and control groups.
- Nerves in non-implanted limbs of tumor-bearing mice showed no changes.
Conclusions:
- This study does not support previous reports of MISO-induced changes in NCV.
- Peripheral nerve function alterations observed in tumor-bearing mice are likely due to tumor mass effect, not Misonidazole toxicity.